Soluble dietary fiber (Fibersol-2) decreased hunger and increased satiety hormones in humans when ingested with a meal

Nutr Res. 2015 May;35(5):393-400. doi: 10.1016/j.nutres.2015.03.004. Epub 2015 Mar 18.

Abstract

We hypothesized that a digestion-resistant maltodextrin, Fibersol-2 (Archer Daniels Midland/Matsutani LLC, Decatur, IL, USA) may impact satiety by decreasing hunger, prolonging satiation, and/or increasing peripheral satiety signals. In a randomized, double-blind, placebo-controlled crossover study, healthy subjects (9 men and 10 women) underwent 3 treatments in which they consumed a standardized meal with a tea containing 0, 5, or 10 g of Fibersol-2. A visual analog scale questionnaire was given in 30-minute intervals to measure subjective appetite and satiety. Blood was drawn just before the meal (time 0) and at 30, 60, 90, 120, 180, and 240 minutes after meal for measurements of plasma ghrelin, cholecystokinin, gastrin, peptide YY, gastric inhibitory polypeptide, and glucagon-like peptide-1, all by enzyme-linked immunosorbent assay. There were significant delays in hunger and increased satiety for 1.5 to 2 hours after treatment with 10 g of Fibersol-2. These delays did not occur after ingesting 0 or 5 g Fibersol-2 at any time. Control and 5 g Fibersol-2 treatments did not suppress increases in hunger postmeal; hunger scores increased and satiety scores decreased significantly (P < .05) at all time points relative to the first postmeal assessment. Plasma peptide YY and glucagon-like peptide-1 were significantly increased by the ingestion of meal with tea containing 10 g Fibersol-2 compared with 0 or 5 g Fibersol-2 (P < .05). This study demonstrated that 10 g Fibersol-2 with a meal stimulated production of satiety hormones and enhanced satiety.

Trial registration: ClinicalTrials.gov NCT01305291.

Keywords: Cholecystokinin; Dietary fiber; Glucagon-like peptide-1; Glucose-dependent insulinotropic peptide; Peptide YY; Satiety.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Appetite Depressants / administration & dosage
  • Appetite Depressants / chemistry
  • Appetite Depressants / therapeutic use*
  • Body Mass Index
  • Cross-Over Studies
  • Double-Blind Method
  • Enteroendocrine Cells / metabolism
  • Female
  • Glucagon-Like Peptide 1 / agonists*
  • Glucagon-Like Peptide 1 / blood
  • Glucagon-Like Peptide 1 / metabolism
  • Humans
  • Lunch
  • Male
  • Middle Aged
  • Overweight / blood
  • Overweight / diet therapy*
  • Overweight / metabolism
  • Peptide YY / agonists*
  • Peptide YY / blood
  • Peptide YY / metabolism
  • Polysaccharides / administration & dosage
  • Polysaccharides / chemistry
  • Polysaccharides / therapeutic use*
  • Prebiotics* / administration & dosage
  • Satiety Response*
  • Solubility
  • Tea
  • Viscosity
  • Young Adult

Substances

  • Appetite Depressants
  • Polysaccharides
  • Prebiotics
  • Tea
  • Peptide YY
  • maltodextrin
  • Glucagon-Like Peptide 1

Associated data

  • ClinicalTrials.gov/NCT01305291